help Will. quarter and morning, off goal business: clinical, important throughout a you terrific us. financial. to we joining areas in And our advancements and everyone, to recent the necessary made momentum to for core made XXXX the advance across is We progress is start. a first the to better corporate Good for patients. Thanks, our thank creating weeks all cancer path deliver and
patents U.S. growing to an and the providing in of patent with strategy. currently from business issued countries. in jurisdictions, property applicable the X by Bio-Path's in XX Japan. intellectual portfolio Australia technology Last applications our portfolio exciting begin patent XX in protection issued foreign filing includes and We announced update and patents newly patent month, we I'll Mexico, estate. patents our receipt issued expanded our
safeguards creates protection to a our build competencies. value would our it be efforts We around is our and to deterrent platform core around competitors technology continue our as
we now have our product the to progress candidate, prexigebersen. made lead Turning with
reported frontline decitabine AML, of myeloid we combination and results treatment with our II of Phase for last Stage interim therapy prexigebersen in acute leukemia, clinical As you or trial from X year, the positive know, of venetoclax.
open-label, is study in study prexigebersen our cohorts and venetoclax combination X with AML II in the X-stage X untreated previously multi-center amended an Stage and of Phase AML. an of in decitabine patients of trial Recall, is It AML. refractory/relapsed with
resistant a complete patients combination remission A third who complete of remission, this venetoclax includes prexigebersen includes X-drug refractory/relapsed intolerant partial The incomplete primary for and with treating and complete AML which are patients study of the hematologic recovery hematologic be or achieve who decitabine. cohort recovery. remission with endpoint number with will
based compelling but not administered X current initial AML X analysis refractory/relapsed Cohort that therapies. show the better prexigebersen therapy also for unsuitable from and efficacy and X demonstrated standard data chemotherapy, interim combination only of was diagnosed high-risk, newly were signals and Efficacy and considered safely to than Cohort X Cohort patients Cohort in
in relapse refractory current are encouraging as treatment a challenging This is population options suboptimal. particularly which are patients
On of and to who U.S. FDA pursue plan for or Bio-Path designation AML patients the strength these without expedited receive Food to unacceptable are side for chemotherapy Drug data, Track programs currently effects. in intensive unable prexigebersen Fast treatment we Administration
older. and age serious front. left progress that regulatory Bio-Path need only forward you to have XX unmet median of look represent of our years a of If keeping and survival XX the and elderly to on meets. clear these be to months, tend a untreated, patients We These patients apprised X
now program, to BPXXXX Turning Bcl-X. our which targets
for of correlated all up to been driving High AML. responsible survival diagnosed for prognosis is of with expression XX% Bcl-X know, Bcl-X patients cell with cancers. you As has in poor
CLL AML and neutralizing the protein anti-apoptotic for against patients. untreated patients lymphocytic the chronic domain. has treatment protein's Bcl-X shown activity works an is BHX or It Venetoclax by improved leukemia, and
allogeneic some invariably BHX occurs mutation relapse oftentimes due over of However, patients time. the treated domain cell to disease exception hematopoietic with with transplantation,
protein. Bcl-X the targets also BPXXXX
not and However, BHX BPXXXX activity domain. RNA the Bcl-X messenger is based on blocking the
result, we AML venetoclax provide patients that could believe previously who relapsed, have patients received a treatments. including alternative for venetoclax As an who BPXXXX
the for dosing cohort scheduled patients with of toxicity, resistant BPXXXX monotherapy A is treated announced an escalation there AML, design. standard cohort be BPXXXX X+X we treat a our month, including of evaluable Last the to second of completion patients. Phase dose refractory/relapsed total clinical patients a tested. X are to dose-limiting I/Ib venetoclax dose portion trial would require which Unless X of of and additional
is there of was considered doses per approved X cycle first milligrams toxicity. dose starting The square Phase I/Ib over meter, a days. combination XX cohort monotherapy BPXXXX dose assess in efficacy study BPXXXX XX week will with doses decitabine of X for treatment and commence administered after a AML is no refractory/relapsed portion the The and to total the per X of of The dose-limiting expected patients. in over and cohorts completion weeks of safety
X+X BPXXXX refractory/relapsed and of for refractory/relapsed per of first In leukemia, CLL. of of total in BPXXXX the cohort treatment a treated I dosing square or announced of monotherapy dose X January, meter. Phase a patients will with cohorts lymphoma starting evaluable design, we standard X dose chronic of of dose the clinical be trial over completion the with escalation A evaluating our XX BPXXXX, lymphocytic portion milligrams
We days. over cohort XX approved second administered patients for doses doses in is weeks, objective of tolerability meter. to The over keeping dose of open and primary is milligrams apprised progress resulting escalating our X BPXXXX. cycle the here. of week XX you treatment Enrollment of square X study the now per evaluate of for per is X look to safety forward doses The the
a in the and tumors, breast most challenging clinical of Next, today's the some trial solid is cancer, endometrial, triple-negative sharing cancers with BPXXXX-A let's drug nanoparticle treat to modified properties. toolkit. therapeutic with BPXXXX-A patients enhanced pancreatic our to substance including ovarian, from prexigebersen with I/Ib turn Phase product of same
later has our for study we such endometrial This year. We provide outcomes, conducted cancer evaluate solid that ovarian and will poor often potentially to patients clinical trial cohort is from it recurrent this leading safety look benefit several cancer in is The patients. being tumor and with may initially readout the centers forward at and completion patients. diagnosed and data hope the
we've let's made activation the such which is cancer. colon Its that targets and processes a cancers, many tumor drug tumorigenic ovarian, aberrant protein. STATX transcription the overexpression Finally, STATX proliferation, factor breast, resistance. progress BPXXXX and as liver metastasis regulates review various characterize with and including lung,
cells. Activation also cancer cells resistance. of in STATX colorectal the cancer breast role therapeutic resistance malignancies and made migration Its in STATX promotes a and ovarian tumor taxol pathway in potential promotes cancer STATX numerous target. initiation, X-FU
combination ovarian These line results oligodeoxynucleotide taxol with the with cells X-FU. are enhances expression BPXXXX STATX that reduces is sensitivity and previous liposome-incorporated a in STATX and efficiently antisense breast novel and of which cancer is activity with gemcitabine strongly a patients ductal adenocarcinoma. solid strategy for in in Together, novel displayed plus work BPXXXX results that tumors. enhanced BPXXXX these suggest advanced antitumor therapy pancreatic
will we safety to a plasma to After method application drug detection for or FDA. that investigational complete an identified final period oligo extended testing, us testing the needed submission IND have for in enable to of finalize an new
excited has therapy options. are challenging We limited to first our validation launch that cutting-edge particularly treatment in-human of indication especially in cancer an this
a agreement. strengthened and additional These to million underpinning call financials, the a our development I'd Before over quarter with million $X.X offering turn review funding through clinical we've financial execute to registered provides recent first our weeks the plan. that highlight from balance like our for direct At-The-Market of sheet offering which $X.X in Anthony to I our
With I'll Anthony program that, for review of Anthony? the balance financials now brief our highlights. to over sheet a Price with turn along
